Our vision is to lead the development of new molecules with agonistic action to the AT2 receptor into successful clinical drug entities.
The company will pioneer exploration of AT2 activation, and commercialise the clinical potential in the different fields where AT2 agonism addresses significant but yet unmet medical needs, such as the consequences of hypertension and neurological disorders.
By way of this, we will be able to improve the clinical outcome for cardiovascular diseases, as well as develop our concept into drugs for other important diseases where inflammation or neurodegeneration/damage are prominent
aetiologies, some indications with Orphan Drug status.
